Using genomics to guide treatment for glioblastoma. Read more about Using genomics to guide treatment for glioblastoma.
Genomic architecture of pharmacological efficacy and adverse events. Read more about Genomic architecture of pharmacological efficacy and adverse events.
Genetic mutations in head and neck cancer: utilizing existing treatments. Read more about Genetic mutations in head and neck cancer: utilizing existing treatments.
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Read more about The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
Pharmacogenomics of membrane transporters: past, present and future. Read more about Pharmacogenomics of membrane transporters: past, present and future.
Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network. Read more about Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network.
New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Read more about New CYP2A6 gene deletion and conversion variants in a population of Black African descent.
Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Read more about Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy.
Population differences in breast cancer severity. Read more about Population differences in breast cancer severity.
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Read more about Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
